Alterity Therapeutics Limited
Officers & Directors
Geoffrey P. Kempler, age 70, is Chairman of the Board of Directors and a founder of the company. He has a background in psychology and experience in investment and business development. Kempler served as CEO from November 1997 to August 2004 and from June 2005 to January 2021. He has held leadership roles at Opthea Limited, Ausbiotech, the Turner Institute of Brain and Mental Health at Monash University, and Hexima Ltd.
David A. Stamler, M.D., age 64, has been Chief Executive Officer since January 2021. He previously served as Chief Medical Officer and Senior Vice President of Clinical Development from May 2017. Stamler has experience at Teva Pharmaceutical Industries and Auspex Pharmaceuticals and holds an M.D. and B.A. in Biology from the University of Chicago.
Lawrence B. Gozlan, age 46, has been a Director since August 2011. He is Chief Investment Officer and Founder of Scientia Capital, a life sciences investment fund. Gozlan was formerly an institutional biotechnology analyst at QIC and senior biotechnology analyst at Foster Stockbroking Pty Ltd, with corporate finance experience at Deloitte. He is also a Director of Opthea Limited and holds a Bachelor of Science with Honors from the University of Melbourne.
Peter A. Marks, age 69, has been a Director since July 2005. He has over 35 years of experience in corporate advisory and investment banking, specializing in life sciences and biotechnology. Marks has served on the boards of Elsight Limited, Nyrada Inc., Noxopharm Limited, Iris Metals Limited, and EverGreen Lithium Limited. He holds an MBA, Bachelor of Economics, Bachelor of Law, and Graduate Diploma in Commercial Law.
Brian D. Meltzer, age 71, has been a Director since December 1999.
Phillip Hains, age 65, served as Company Secretary and Chief Financial Officer until resigning as CFO on September 30, 2024, and as Company Secretary on November 17, 2024.
Abby Macnish Niven, age 43, was appointed Company Secretary on November 18, 2024, and Chief Financial Officer on September 30, 2024.
Alterity Therapeutics Limited currently has 11 employees.
News about Alterity Therapeutics Limited Key Personnel |
Alterity Therapeutics Expands Leadership Amid Promising Advances in Neurodegenerative Treatment The Shift in Leadership StrategyIn a significant move on November 18, 2024, Alterity Therapeutics appointed Abby Macnish Niven as its Company Secretary, a role she assumes in tandem with her recent appointment as Chief Financial Officer. This dual role comes during a pivotal time for the Melbourne-based biopharmaceutical company, which is gaining attention for its innovative approach to combating neurodegenerative diseases. Previously held by Phillip Hains, the Company Secretary position will now be instrumental in steering Alterity s strategic initiatives as it develops therapies targeting complex conditions, par...
|
In a recent shareholder letter, Alterity Therapeutics highlighted significant advancements in their pipeline, sharing updates on key upcoming milestones. The company has also generated preliminary data from the ATH434-202 Study, with expectations for the completion of the ATH434-201 Study in November 2024. These developments hold immense potential for the future prospects of Alterity Therapeutics.
I. Pipeline Advances:
Alterity Therapeutics has made notable progress in its pipeline, signaling a ramped-up effort in developing innovative therapies. The preliminary data from the ATH434-202 Study, expected in the first half of 2024, serves as an important stepping stone towards advancing their ...
|
|
|
